(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.69%.
Quoin Pharmaceuticals's earnings in 2026 is -$19,587,909.On average, 8 Wall Street analysts forecast QNRX's earnings for 2026 to be -$1,095,653,903, with the lowest QNRX earnings forecast at -$1,300,135,834, and the highest QNRX earnings forecast at -$768,005,279. On average, 7 Wall Street analysts forecast QNRX's earnings for 2027 to be -$441,113,311, with the lowest QNRX earnings forecast at -$733,283,201, and the highest QNRX earnings forecast at -$307,202,112.
In 2028, QNRX is forecast to generate -$389,896,145 in earnings, with the lowest earnings forecast at -$581,683,079 and the highest earnings forecast at -$225,987,760.